Compare AEHL & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEHL | AIMD |
|---|---|---|
| Founded | 1993 | 1984 |
| Country | China | United States |
| Employees | N/A | 41 |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 13.3M |
| IPO Year | 2009 | N/A |
| Metric | AEHL | AIMD |
|---|---|---|
| Price | $0.69 | $1.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 155.2K | 43.0K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $1.26 |
| 52 Week High | $6.53 | $4.50 |
| Indicator | AEHL | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.23 | 39.45 |
| Support Level | $0.48 | $1.38 |
| Resistance Level | $1.13 | $1.75 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 30.76 | 8.00 |
Antelope Enterprise Holdings Ltd operates in three reportable operating segments: Business Management Consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting; Natural Gas Power generation, which was in the initial development stage; and Live-Streaming e-commerce segment, providing a one-stop solution for customers to enable them to utilize the growing sales channel of livestreaming ecommerce. The business of the Company is engaged in the PRC and the United States.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.